Repurposing crizotinib to target RIPK1-dependent cell death.
Yu Y, Li M, Fu S, He X, Hu X, Zhu G, Wang J, You X, Mou Y, Ye Z, Wei J, Zha Y.
Yu Y, et al. Among authors: wei j.
Int Immunol. 2023 May 8;35(5):221-230. doi: 10.1093/intimm/dxac061.
Int Immunol. 2023.
PMID: 36534968